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Clinical and histological diversity of the Jymphoproliferative disorders
in kidney transplant recipients. Y. Le Meur, P. Peyronnet, C. Lavignac, .4.
Jaccard, D. Bordessoule, and C. Leroux-Rohert, Departments of Nephrology
and Hematology, University Hospital, Limoges, France. Following kidney
transplantation, lymphoproliferative disorders (LD) are encountered at a
frequency of 1%. The onset of these disorders is correlated with the
degree of immunosuppression. The mortality of these LDs is elevated
(> 50%), especially in forms which occur after 12 months of transplanta-
tion. Since 1984 we have performed 211 kidney transplantations. The
majority of patients received sequential quadruple-drug immunosuppres-
sive therapy consisting of antilymphocyte globulin (ALG) for 10 or 14
days, azathioprine, corticosteroids, and cyclosporine, which was instituted
upon discontinuation of ALG. Episodes of rejection were treated with
corticosteroids and, if unsuccessful, by re-treatment with ALG. During
this period, a diagnosis of LD was established in 10 patients. The mean
duration between transplantation and diagnosis was 55 months: 4 were of
early onset (within 12 months of transplantation) and six late (after 5 to 9
years). Rejection occurred in 2 patients, one of whom was steroid-resistant
and required ALG. None had received OKT3. Signs leading to the
diagnosis were: fever (5), lymphadenopathy (4, of which 3 arose from the
graft hilum), digestive tract symptoms (2), and a histological diagnosis of
a pneumonectomy specimen for lung cancer (I). The extranodal sites of
these LDs were: the graft (I), stomach (2), gingiva (I), meninges (1), and
bone marrow (I). Histologically there were: 8 cases of large-cell B
lymphoma (of which 4 were monotypic), 1 mononucleosis-like LD, and I
Malt Lymphoma (Mucosae associated lymphoid tissue). A search for
Epstein Barr virus by immunohistochemistiy (LMPI) or in situ hydridiza-
tion (EBER) was positive 7 times. EBV serologic testing showed evidence
of residual antibodies (8) and reactivation (2). Treatment consisted of
decreasing immunosuppressive therapy (3), combined with surgical re-
moval of the graft (3), and/or chemotherapy (5). After a mean follow-up
of 25 months, I patient died of lung cancer, and 9 are still alive (7 are in
complete remission, of whom 4 have undergone chemotherapy and 2 are
presently receiving it). Graft loss occurred in 3 cases. In 2 patients,
azathioprine was reinstituted after discontinuation of chemotherapy, and
in the patient with mononucleosis-like LD, low doses of cyclosporine have
been reintroduced. Conclusion: in our series, we found a high frequency
(>4%) of LD. Chemotherapy was used successfully in 5 cases. Despite
the unfavorable histological diagnoses, their late onset, and the use of
intensive chemotherapy, these LDs had favorable outcomes.
Whole blood production of monocytic cytokines (LL-lp, IL-iRA, IL-6,
IL-6 R, TNFa) in hemodialyzed patients. Y. Le Meur, C. Leroux-Rohert,
and V Praloran, Departments of Nephrology and Hematology, University
hospital, Limoges, France. Monocytes of hemodialyzed patients (HD)
present phenotypic and functional signs of permanent activation. Studies
of cytokine production by isolated mononuclear cells (PBMC) after
stimulation using various doses of activators gave contradictory results but
generally showed an increase of production in HD patients compared to
controls. We tested the production of cytokines in whole blood cultures
(WBC) stimulated with suhoptimal doses of activators. Diluted blood
(1/10) of 10 HD patients (harvested before dialysis) and 10 controls (C)
was cultured without activators or with LPS (1 and 3 xg/ml), or PHA (2.5
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jxg/ml). Supernatants were collected after 24 and 48 hours of culture at
37°C, 5% CO,. Spontaneous production of lL-lp, IL-6 and TNF-a was
low in the two groups. PHA induced no production of IL-Ip and a poor
production of IL-6, and TNFa without any difference between HD
patients and C. At 24 and 48 hours, the production of IL-113, IL-6 and
TNF-a was significantly lower in HD patients as compared with controls
when LPS concentration was I pg/mI but became similar when LPS
concentration was 3 pg/mI.
24 Hour cytokine_production by WBC stimulated with 1 pg/mI LPS
IL-I (pg/mI) IL-6 (pg/mI) TNF (pg/mI)
HD patients (N = 10) 901 467 6037 3000 1728 599
Controls (N = 10) 2065 726 8960 2300 3089 851
Spontaneous production of IL-6R was superior in HD patients and did not
increase after stimulation by LPS or PHA in the two groups. IL-iRa
production was similar in the two groups spontaneously or after stimula-
tion. WBC was used because it allowed us to study the cytokine production
by cells inside their complex cellular and humoral network. Despite
evidence of monocytic activation, we found a decreased production of
monocytic cytokines in HD patients when WBC was stimulated by
suboptimal doses of LPS.
A simple and economical solution to reduce the risk of bacterial
contamination in the dialysate using a dialysate filter (DIASAFE). Y. Le
Meur, C. Lagarde, D. Bénévent, M. Mounier, and Claude Leroux-Robert,
Department of Nephrology, University Hospital, Limoges, France. Bacterial
counts of the dialysate are often below accepted standards, particularly,
with home dialysis. "On-line" filtration consists of inserting a filter in the
dialysate circuit just before the dialyzer, thus ensuring the highest quality
of dialysate. We studied the efficacy of the dialysate filter DIASAFE
(polysulfone, 40 jrm), by adding it to Fresenius 4008 B dialysis generator
in 9 patients on home dialysis. The water treatment system consisted of a
10 j.m filter, a softener, a charcoal filter, a 1 xm filter, and a reverse
osmosis unit. Monthly bacteriological cultures were obtained from the
trocar site, by withdrawing 300 ml of water before and after the filter in
sterile containers that were stored and transported at 4°C. Cultures were
performed with two culture media, PCA and TGEA, and two volumes, I
ml and 100 ml (filtered and rinsed using a (1.45 ttm filter). They were
inspected at 48 hours and 7 days, results expressed in CFU/ml (colony
forming unit). A search for endotoxins was performed using a semiquan-
titative Limulus test with a detection threshold of 0.12 EU/mI. Using
classical culture techniques (1 ml in PCA medium, colony count at 48
hours and 7 days), the mean value of samples collected before filtering (45
in 9 patients) was 290 529 CFU/ml, and in 5 of 9 patients the bacterial
count was constantly high (> 100 CFU/ml). After filtering, less than 5
CFU/ml were found in 100% of cases and 0 CFU/ml in 88%. Filter efficacy
was more fully assessed with culturing techniques of greater sensitivity
using 100 ml of PCA (the results correlated perfectly with TGEA):
Before filter After filter
Culture at 48 h (CFU/100 ml), N = 45 774 432 1.55 3.54
Culture at7 days (CFU/i00 ml), N = 45
—_1180 783 2.02 4.34
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A search for endotoxin was performed 35 times before filtering and was
positive in 20 (>0.12 EU/mI 4, > 0.25 EU/mI 7, > 0.5 EU/mI 5, > I
EU/mI 5). After filtering, the search was negative (< 0.12 EU/mI) in 100%
of the 35 samplings. The filters were studied over a mean utilization period
of 616 hours. There were no signs of membrane obstruction. We believe
it is reasonable to change routinely the filter after 1000 hours of
utilization. Conclusion: The DIASAFE dialysate filtering system ensures a
high-quality dialysate, particularly in home dialysis. When used as we
recommend (1000 hours), the extra expense per dialysis session is low.
Furthermore, this system can be used in dialysis centers to improve
dialysate quality, permitting the safe use of highly permeable membranes.
Clearance of complement factor D by high-flux membranes. I. Naka-
nishi, A. Moutaharrik, Y Akagaki, H. Kitamura, and Y Tsubakihara,
Department of Nephrology, Osaka Prefectural Hospital, Japan; Department
of Nephrolo, Faculté de Médecine de Casablanca, Morocco; and Depart-
ment of Immunology, Osaka Center for Adult diseases, Osaka, Japan. Factor
D (molecular wt, 2400) is a serine protease participating in the formation
of C3 convertase of the alternative pathway of the complement. This
factor accumulates in end-stage renal failure. Recently, growing interest
has focused on high-flux membranes (HFM) which were used to dialyze
f32-microglohulin in ESRD patients. In the present work, we investigated
whether factor D is removed by HFM. Five patients on hemodialysis (HD)
were dialyzed with 10 different kinds of HFM. Measurement of factor D
was performed with hemolytic assay using a complex venom factor and
human factor D. Sampling was performed at 3 points: arterial line, venous
line and dialysate effluent at 20 minutes and 210 minutes after starting
HD. Sieving coefficiency (SC) and removal rate by adsorption (RRA). SC
at 20 minutes (SC 20) showed that etbylenevinylalcohol, polysulfone,
cuproammonium rayon were superior compared to saponified cellulose
which were superior to polyacrylonitrile. SC 20 compared to SC 210
showed better epuration with ployesterpolymrelloy, followed by polyacry-
lonitrile. The lowest ratio was obtained with polysulfone and polymethyl-
methacrylate. The RRA at 20 minutes (RRA 20) was better with
polyaciylonitrile, followed by polysulfone and polymethylmethacrylate,
followed by polessterpolymrelloy and cuproammonium rayon and ethyl-
enevinylalcohol. The lowest RRA 20 was obtained with cellulose acetate
and saponified cellulose. The comparison RRA and RRA 210 did not
show any significant differences. We conclude that factor D which
accumulates in end stage renal failure can be removed by HFM, but the
degree of SC and RRA is remarkably different between different mem-
branes.
Evidence for an endogenous inhibitor of fucosyltransferase in the
kidney and its modulation by cyclosporine. R. Cahen, S. Whitaker, M.
Labeeuw, P. Louisot, and A. Martin, Service de Nephrologie, Centre
Hospitalier Lyon Sud, Pierre Bénite, and JNSERN-CNRS U189, Faculté de
Médecine Lyon Sud, Oullins, France. We have previously shown that
cyclosporine (CsA) at a toxic dose in the rat altered enzymatic protein
glycosylation in the kidney. This fact prompted us to look for regulatory
proteins involved in the glycosylation processes in the kidney and to assess
their possible changes induced by CsA. Kidneys from normal adult
Sprague-Dawley rats were homogenized and fractionated by centrifuga-
tion. Fractions were incubated in a cell-free standardized system in the
presence of a partially purified a(1-2)-fucosyltransferase, donor substrate
GDP-fucose and acceptor substrate asialofetuin. We identified in the
soluble cytoplasmic compartment an endogenous protein inhibiting fuco-
syltransferase activity. Purification by DEAE-cellulose chromatography,
ammonium sulfate fractionation and hexyl-agarose chromatography in-
creased by 100-fold the specific inhibitory activity, as expressed in units of
inhibitor/mg proteins. One unit of inhibitor was defined as the amount of
proteins giving a 50% inhibition of fucosyltransferase activity in standard-
ized conditions. Furthermore, rats were divided into 4 groups of 4 animals
and injected subcutaneously for 30 days with normal saline or cremophor
or CsA at 2 or 20 mg/kg/day. After the 3 purification steps, inhibitory
activity in the kidney was, respectively, in the 4 groups: 116 16, 123
12, 110 2,353 59 U/mg proteins (x Sn). Thus, inhibitory activity was
significantly increased in rats given CsA at a toxic dose and was similar to
controls in rats given a therapeutic dose. In conclusion, we identified in the
rat kidney an endogenous protein inhibiting fucosyltransferase activity.
CsA at a toxic but not at a therapeutic dose increases the activity of this
endogenous inhibitor. Considering the known biological roles of glycopro-
teins, this effect may contribute to the mechanisms of cellular injury in
chronic CsA nephrotoxicity.
Control of Na,K-ATPase activity through protein kinase A phosphory-
lation of its a-subunit in the thick ascending limb of Henle. M. Kiroycheva,
M. Rousselot, H. Favre, and E. Féraille, Clinique de Néphrologie, Hôpital
Universitaire Alexandrovska, Sophia, Bulgaria and Division de Nephrologie,
Hôpital Cantonal Universitaire de Genève, Genève, Switzerland. Hormones
whose receptors are coupled to the activation of adenylate cyclase
stimulate sodium reabsorption by the thick ascending limb of Henle. This
effect, which relies on the activation of protein kinase A (PKA) by
intracellular cyclic AMP (cAMP), participates in the genesis of the
corticopapillary osmotic gradient. This sodium reabsorption process de-
pends on the activity of Na,K-ATPase which is localized in the basolateral
membrane domain. Recent studies have shown that, in transfected cells,
Na,K-ATPasc activity could be modulated by direct phosphoiylation of its
a-subunit by PKA. The aim of this study was to determine the physiolog-
ical role of the phosphorylation of Na,K-ATPase by PKA in the rat
medullary thick ascending limb of Henle. For this purpose we analyzed, in
isolated tubules, the effect of the activation of PKA on: (1) the transport
activity of Na,K-ATPase measured by ouabain-sensitive 'Rb uptake; and
(2) the phosphorylation of the Na,K-ATPase a-subunit measured by
autoradiography after immunoprecipitation. The activation of PKA by
exogenous cAMP (1 mwt dibutyryl cAMP or 8-bromo cAMP) or by
endogenous cAMP (10 zM forskolin plus 0.1 mrvi IBMX) stimulated 8'Rb
uptake by about 40% and increased 3- to 5-fold the phosphorylation of the
Na,K-ATPase a-subunit. These effects of cAMP were prevented by a
specific PKA inhibitor (H89) but were not altered by a specific protein
kinase C inhibitor (GF109203X). The time-course and the dose-depen-
dence of the effects of cAMP on the activity and the phosphorylation of
the Na,K-ATPase were similar. In conclusion, these results show that in
the rat medullary thick ascending limb of Henle: (1) the transport activity
of Na,K-ATPase is stimulated through phosphorylation of its a-subunit by
PKA; and (2) the stimulation of the activity of Na,K-ATPase participates
in the increase in sodium reabsorption in response to hormones coupled
to the activation of adenylate cyclase.
Proton NMR spectroscopy study of kidney preservation and normo-
thermic reperfusion. T. Hauet, D. Mothes, f.M. Goujon, J.C. Caritez, and
M. Eugene, Laboratoire de Chirurgie expérimentale Ct INRA Le Magneraud,
Surgeres, and Se,vice de Néphrologie, Centre Hospitalier, La Rochelle,
France. Proton nuclear magnetic resonance (NMR) spectroscopy is an
important analytical technique for body fluids, which does not require
sample preparation. The aim of this study was to assess the functional
activity of shared kidneys from large white pigs after prolonged cold
storage (CS) with Euro-Collins. Kidneys were flushed in situ and imme-
diately perfused or cold stored before normothermic perfusion. Three
groups of kidneys were used: GI (control, N = 6), kidneys immediately
perfused; G2 (24 hr CS and reperfusion); G3 (48 hr CS and reperfusion).
Kidneys were perfused for 2 hours at 37°C. The perfusion flow rate was
adjusted to maintain the mean arterial pressure at 100 mm Hg via renal
artery. The basic perfusion medium consisted of a freshly prepared Krehs
solution containing creatinine (85 jzmol/liter), bovine serum albumin (50
g/L), and 5 mI/liter of a mixture of 22 L-amino acids in concentrations
between 0.2 and 2.0 mmol/liter. The perfusate was oxygenated by bubbling
with a gas mixture 02 (95%) and CO2 (5%), bringing the pH to 7.4. Urine
and perfusate samples were collected at 15,30,45,60,90 and 120 minutes
during perfusion for biochemical and proton NMR spectroscopy studies.
Optical and electron microscopy was performed after CS and perfusion.
The following parameters were compared: perfusate flow rate (PFR),
glomerular filtration rate (GFR), fractional sodium reabsorption
(FRNa'), and glucose excretion. The ratios of Trimethylamine-N-oxidc
(TMAO), lactate (Lac), acetate (Ace) and alanine (Ala) to creatinine (Ct)
were calculated from urine NMR spectra. Results: PFR was lower for G3
(P < 0.01), related to more severe interstitial edema. GFR was lower for
G3 (P < 0.001). FRNa was lower for G3 (P < 0.001) and glucose
excretion was higher in this group, related to worse proximal tubular
functions. TMAO/Ct, Ace/Ct and Lac/Ct were higher for G3, related to
more severe ischemic injury. These results were correlated with histolog-
ical data. Alanine excretion was also higher in G3, related to impairment
of proximal tubular function. A new peak (Pie X) was detected in urine
from kidneys of G3. An identical peak has been detected in urine and
plasma from intensive care patients. From a technical point of view, no
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other method is able to determine in the same experiment the presence of
TMAO, amino acids, Lac and Ace and at the same time, uncover new
biochemical markers.
Post-transplant erythrocytosis treatment with losartan .1. Rivalan, A.
Haddj-El Mrabet, M.L. Lombard, M.P. Morin, E. Laruelle, V Joyeux, and P.
Le Pogamp, Nephrology and Transplantation Unit, CHRU Pontchaillou,
Rennes, France. Post-transplant erythrocytosis (PTE) is a common com-
plication affecting nearly 20% of renal transplant patients. Usually PTE
occurs in the first two years after transplantation in patients with retained
native kidneys and excellent graft function. Despite unknown pathophys-
iology, effective drug treatments do exist and currently ACE inhibitors are
the drugs of choice. ACE inhibitors may act via the renin system by
lowering Ang II or independently by increasing the plasma level of
N-acetyl-seryl-aspartyl-lysyl-proline, a peptide that inhibits erythropoiesis.
Little is known about losartan in PTE; we tried to assess its efficacy in this
setting. Patients and methods: Seven patients (5 men), after informed
consent, entered into this open study. Four of them were newly diagnosed
PTE. The 3 others were patients already on ACE inhibitors for PTE in
whom ACE inhibitors were stopped and erythrocytosis rapidly recurred
after 2, 3, and 4 months. These patients had been treated for 10, 14 and 48
months; Six were still hypertensive on hypotensive treatment. Graft
function was stable. Immunosuppressive regimen was kept constant during
the study. The patients had been transplanted for a mean of 32 months
(10—72). Losartan was initiated at 25mg od and if needed increased to 50
mg od. Patients were seen as outpatients and their previous hypotensive
drug regimen was titrated as needed.
Results TO Month I
Hb gIdi 17.7 0.93 16.65* 1.05
Ht 52.45 2.24 49.24* 2.91
EPO mUl/mI 12.37 5.84 8.31 2.88
'Cr pmol/liter 118.14 31.87 117.14 26.1
CsA TO 150.28 23.02 157.71 33.98
Uric Acid pinol/liter 423.28 124.11 375.42* 72.64
Results Month 2
Hb g/dl 15.95* 0.92 P < 0.05
I-It 46.88* 2.86 P < 0.05
EPO mUl/mi 10.45 1.97 NS
Pc, pinol/liter 117.85 29.35 NS
CsA TO 171.33 47.04 NS
Uric Acid pmol/liter 363.42* 82.78 P < 0.05
Conclusions: (1) Losartan is effective in the treatment of PTE, irrespective
of plasma Epo levels. Given its very specific action this is a further
argument for an ANG IT-mediated mechanism of ACE-inhibitors in PTE;
(2) Losartan does not decrease significantly the plasma levels of erythro-
poietin (EPO). However, in all the patients with inappropriately high
levels before treatment, a decrease in EPO levels was noted. No correla-
tion was observed between Hb and EPO decrease; (3) Losartan has no
deleterious effect on graft function in this setting of PTE; (4) Cyclosporin
metabolism appears not to be affected by Losartan; (5) Losartan produces
a moderate decrease in plasma uric acid levels.
Assessment by proton NMR spectroscopy of two preservation solutions:
Euro-Collins (EC) and University of Wisconsin (UW). T Hauet, D.
Mothes, C. Godart, J. C. Caritez, M. Carretier, and M. Eugene, Laboratoire de
Chirurgie Expérimentale et INRA Le Magneraud, Surgeres, France, and
Service de Néphrologie, Centre Hospitalier, La Rochelle, France. The
understanding of the ischemia reperfusion phenomena remains an impor-
tant challenge in transplantation and during the severe hypotensive
phenomena. The study of the urine in proton nuclear magnetic resonance
(NMR) spectroscopy allows a quantitative study of different metabolites
such as the Krebs cycle compounds. The aim of this study was to compare
two preservation solutions used in kidney transplantation (EC and UW).
We used an isolated perfused pig kidney model for the functional study.
Three groups of six kidneys from large white pigs were studied: GI
(control) kidney immediately perfused, G2 t48 hr cold storage (CS) in EC
and reperfusionl, G3 (48 hr CS in UW and reperfusion). After CS, kidneys
were perfused at 37*C for 2 hours with a mean arterial pressure of 100 mm
Hg via renal artery. The basic perfusion medium consisted of Krebs
solution containing creatinine (10 mg/liter), glucose (10 mmol/liter),
bovine serum albumin (50 g/liter) and amino acid mixture (5 mI/liter) and
oxygenated with a gas mixture (02: 95%-C02: 5%). Urine and perfusate
samples were collected 15, 30, 45, 60, 90 and 120 minutes after reperfusion
for biochemical and NMR study. An optical and electron microscopy
study was performed after CS and reperfusion. The perfusate flow rate
was identical between G2 and 03. The weight variation between the end
of CS and reperfusion was higher for G2 (P < 0.05). LDH and N-acetyl-
13-D-glucosaminidase excretion was higher for G2 (P < 0.05). Trimethyl-
amine-N-oxide (TMAO), lactate and acetate excretion was higher for G2
in proton NMR spectroscopy (P < 0.01). These results indicate a more
severe cellular ischemia confirmed by histology. The tubular functions
were better for G3 in NMR spectroscopy, a lower amino acid (alanine and
valine) (P < 0.01) and glucose excretion (P < 0.01). Sodium fractional
reabsorption (FRNa) was lower for G2 (P < 0.01) and pH of urine was
less alkaline (P < 0.01) at t15. Glomerular filtration rate was higher for G3(P < 0.01). Citrate was detected on urine spectra for G3 showing a better
correction of the intracellular acidosis. These results showed clearly better
preservation of the kidneys after 48 hour CS in UW. Proton NMR is an
original technique for the study of ischemia and reperfusion phenomena.
The isolated perfused pig kidney appears to be an interesting model.
Acute renal failure with glomerular bleeding complicating three cases
of cirrhosis of the liver. J.M. Powc, R. Demontis, J.F. Cadranel, C. Guettier,
C. Lagarde, and P. Fievet, Département de Médecine Inteme (Unites de
Nephrologie et d'Hepatologie) Hôpital LaCnnec, Creil, Service de Néphrolo-
gie, CHU Dupuytren, Limoges, Service d'Anatomie Pathologique, Hôpital J.
I/erdier, Bondy, France. We report three patients with IgA nephropathy
associated with cirrhosis of the liver who developed rapidly progressive
acute renal failure with macroscopic hematuria of glomerular origin in the
absence of significant glomerular lesions or hepatorenal syndrome. These
patients (mean age 59 years) had in common the following criteria: normal
renal function before the sudden onset of macroscopic hematuria, durable
macroscopic hematuria and progressive evolution to severe renal failure
necessitating continuous renal remplacement therapy, tubular changes in
the renal biopsy responsible for renal failure (tubular necrosis, variable
amounts of erythrocyte casts in tubular lumen), absence of other cause of
tubular necrosis, exclusive (in one case) or predominant IgA deposition on
immunofluorescence in the mesangium and/or subendothelial area. Cir-
rhosis of the liver (biopsy proven in two cases) was of variable origin:
hemochromatosis, viral (hepatitis C virus), alcoholic. One patient died
during hemodialysis. The two other patients had undergone renal rem-
placement therapy for a mean of 7 I months (spontaneous recovery of
renal function). Two years later, these two patients had stable renal
function (plasma creatinine, respectively, 120 and 210 ,trmol/liter). Only
two similar cases had been previously described, by Praga et a!. In
summary: (1) During cirrhosis of various etiology, acute renal failure with
gross hematuria of glomerular origin (IgA nephropathy) can be observed;
(2) Renal biopsy is necessary to exclude necrotizing glomerulonephritis;
(3) Contrary to hepatorenal syndrome, renal remplacement therapy must
be initiated because spontaneous recovery of renal function can occur.
Influence of apolipoprotein E genotype on the risk for atherosclerosis
in hemodialysis. R. Purgus, J.F. Renucci, R. Planells, A. Barlattier, and M.
Olmer, Departments of Nephrology and Biochemistry, University Hospital(Conception), Marseille, France. Lipid disorders are common in hemodi-
alysis patients with an excessively high rate of morbidity/mortality from
cardiovascular diseases. However, the contribution of dyslipidemia to the
accelerated atherosclerosis seen in this population remains debatable, and
the predictive value of conventional risk factors is limited. Our aim was to
evaluate the influence of a genetic factor on atherosclerosis in our dialysis
patients by identifying a possible link between the carotid intima-media
thickness (TMT), a clinical marker of vascular lesion, and the incidence of
apolipoprotein E (apo E) genotype. Sixty-six non-diabetic, non-smoking
patients (33 F, 33 M) with a mean age of 50.3 years (2O—70), on
hemodialysis for an average of 39.8 months, were studied. They presented
the lipid profile usually observed in hemodialysis with, on average, a mild
hypertriglyceridemia (1.77 0.8 g/liter), elevated levels of Lp(a) (366 ±
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251 mg/liter) and of homocysteinemia (35 13 jxmol/liter), normal total
cholesterolemia (195 0.5 g/liter) and decreased HDL-cholesterol
concentrations (0.36 0.1 g/liter). IMT was measured by high resolution
echo-Doppler and the patients were divided into 2 groups according to a
critical threshold of 0.75 mm: group I (N = 33, 14 F, 19 M), IMT  0.75
and group H (N = 33, 19 F, 14 M), IMT < 0.75 mm. Apo E genotype was
determined by restriction isotyping. The apo E genotype frequency in
group I was E2/0.09, E3/0.7, E4/0.21, and in group II it was E2/0.07, E3/0.9,
E4/0.03. Thus, the relative frequency of E4 was 7 times higher in group I
(0.21) than in group 11(0.03), a statistically significant difference (x2 P =
0.0001) suggesting that the apo E genetic polymorphism might contribute
to atherosclerosis in hemodialysis. We conclude that E4 seems to be a risk
factor for accelerated thickening of the arterial wall and it may predict
high risk patients.
Long-term prognosis of isolated C3 mesangial deposit glomerulone-
phritis. C. Orfila, iC. Lepert, A. Modesto, B. Pipy, and J.M. Sue, INSERM
CJF 91-07 et Service de Néphrologie, CHU Rangueil, Toulouse, France.
Isolated C3 mesangial deposit glomerulonephritis (GN) is a subtype of
ON, characterized by the presence of minimal glomerular lesions with
granular mesangial deposits of C3, without immunoglobulins or other
complement components in patients presenting with gross hematuria or
microscopic hematuria (mH) isolated or associated with proteinuria.
Short-term prognosis (3 years) seems benign. In the literature, long-term
prognosis studies reported discordant results. In previous studies, we
described 40 patients presenting with isolated C3 mesangial deposit GN.
We included these cases in a retrospective analysis of 3800 renal biopsies
studied by immunofluorescence and performed between 1975 and 1995.
We found 88 cases: 13 cases presented with gross hematuria (Group 1), 46
isolated mH (Group H), and 29 had proteinuria associated with mH
(Group III). No patient had renal impairment (RI). By light microscopy,
renal biopsy study showed moderate mcsangial matrix hypertrophia
associated with segmental and focal mesangial proliferation in some cases.
Tubulointerstitial lesions (tubular atrophy in focal areas of interstitial
fibrosis) were demonstrated. Interstitial infiltration was rarely observed.
Arteriolar lesions were present in some cases. All patients had C3 granular
deposits in the mesangial area. No immunoglobulins were present.
Frequent C3 arteriolar deposits, sometimes associated with 1gM, were
observed. Clinical evolution of 60 of these patients was studied. In group
I, 8 patients were followed-up between 5 months and 7 years: 4 presented
with mH and 2 with hypertension, already observed at the time of biopsy
in 1 case. In this group, after a follow-up of 17 years, another patient had
no urinary abnormality. In group II, 26 patients were followed-up between
1 month and 10 years: 21 presented with mH and 4 hypertension (already
observed in 2 cases at the time of biopsy). In this group, 6 patients were
followed-up between 10 and 17 years, I had mH, 2 hypertension, and in 1
case, moderate RI (serum creatinine 158 xmol/liter) was observed. In
group III, 9 patients were followed-up between 1 month and 5 years: 2
presented with mH, 5 with mH and/or proteinuria, and 1 with hyperten-
sion (already observed at the time of biopsy). In this group 10 other
patients were followed-up between 10 and 17 years: 3 presented with mH,
5 had mH and/or proteinuria, 4 had hypertension (already noted at the
time of biopsy in I case) and 3 patients had moderate RI (serum creatininc
133, 139 and 180 jxmol/liter, respectively). In conclusion, 17 patients with
isolated C3 mesangial deposits were followed-up between 10 and 17 years.
Five of these patients presented with de novo hypertension and 4 had
moderate RI. Although prognosis was not totally benign, long-term
evolution (10 years and more) of our series of patients was not as
pejorative as the evolution reported in the literature. Larger series of
patients are needed to specify this evolution.
Effect of a low-protein, low-phosphorus diet on the evolution of kidney
transplant function. D. Morel, P. Merville, C. Deminiere, C. Combe, L.
Potaux, and M Aparicio, Néphrologie, Anatomo-pathologie, Hôpital Pelle-
grin, Bordeaux, France. In the long-term, the function of kidney transplants
is sometimes altered because of a complex process, in which immunolog-
ical chronic rejection and non-immunological phenomena are involved.
The latter are common to most chronic nephropathies and could he
impeded by protein restriction. We studied the long-term effect of a
low-phosphorus (5—7 mg/kg/day), low-protein (0.3—0.4 g/kg/day) diet with
keto acid supplementation in 11 of our kidney transplant recipients. They
had been transplanted from cadavcric donors for 2 to 10 years (median
6.3) before starting the diet. At that time, each of them suffered from
histologically proven chronic rejection and their respective glomerular
filtrations (GFR) ranged from 10 to 32 mI/mm (median 16.9). Ultrasonog-
raphy and Doppler examination were normal in all patients. The tn-
immunosuppressive regimen remained unmodified during the study,
which lasted 12 to 88 months (median 31.9). The evolution of renal
function was assessed on the variations of the regression slope obtained by
plotting creatininemia reciprocals against time. The slope from the 8th
month after starting the diet was compared to that observed during the
pre-diet period. The first 8 months were not taken into account, since
during this period the lesser decrease of creatininemia does not corre-
spond to an amelioration of GFR: it is an artifact induced by the sudden
suppression of creatine and creatinine intake. After at least 3 half-lives of
creatinine (4 months), changes in creatininemia again correlate roughly
with changes in GFR. Thus, the diet results in a significant reduction of
the slope for each patient (Wilcoxson matched pairs signed rank test: P =
0.0033), with individual variations in the intensity of response. Interstitial
scarring associated with a mononuclear infiltrate seemed to be the most
prominent factor of poor prognosis. Patients had no alteration in their
nutritional status, assessed on clinical and laboratory criteria. In conclu-
sion, a very low-protein, low-phosphorus diet appears to slow the long-
term degradation of renal function in kidney transplant recipients, thus
allowing a delay in dialysis onset.
Mesalazine induced interstitial nephritis (IN): A case report. D. Fleuty,
F. Glowacki, R. Binaut, F. Bridoux, B. Mougenot, and Ph. Vanhille,
Department of Nephrology, Valenciennes, and Pathology, Tenon Hospital,
Parfc, France. When used for oral treatment of inflammatory bowel
diseases, Mesalazine can cause chronic IN. Restoration of renal function
after withdrawal of medication does not always occur. We described a case
of Mesalazine associated IN with persistent chronic renal failure due to
delayed diagnosis. Case report: A 22 year-old man with Crohn's disease,
diagnosed in September 1989, was referred for renal failure in September
1995. He had been initially treated by Sulfasalazine (8 months) and then
received Mesalazine 1.5 to 3 g bid, for 5 years. Serum creatinine was 4.5
mg/dl, blood urea level was 106 mg/dl, and inulin clearance was 20.5
mI/mm. Urinary protein excretion was 800 mg/day with leukocyturia
(24.103/ml) but no bacteriunia. Blood pressure was normal: 110/60mm Hg.
The inflammatory bowel disease was quiescent and the only extrarenal
sign was Raynaud's phenomenon. Erythrocyte sedimentation rate was
60/92, complement was normal, and antinuclear antibodies were negative.
Abdominal ultrasonography revealed small kidneys without calcifications.
Renal biopsy showed atrophic tubules, widespread interstitial fibrosis with
some inflammatory infiltrates without glomerular or vascular lesions. No
granuloma was observed and Congo red staining was negative; immuno-
fluorescence study showed no Ig or C deposits. Lip biopsy did not show
any inflammatory lesions or amyloid deposits. Mesalazine was discontin-
ued and 12 months later serum creatininc was 4.0 mg/dl. Conclusion:
Different forms of IN have been described in patients with Crohn's
disease: granulomatous IN or IN with nephrocalcinosis secondary to
enteric hyperoxalunia. In our case, renal pathological features and the
absence of Crohn's disease activity were suggestive of Mesalazine toxicity.
In patients treated with Mesalazine, close monitoring of renal function is
mandatory to prevent the development of progressive renal failure. As
shown by WORLD et al., prompt withdrawal of Mesalazine may lead to
recovery of renal function in early stages of toxicity. In our case, the
presence of risk factors—longstanding treatment and the high whole dose
(4800 g)—was responsible for severe interstitial fibrosis with persistent
chronic renal failure.
